...
首页> 外文期刊>Oncology >The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.
【24h】

The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.

机译:激素受体阳性乳腺癌的自然史:试图破译一个有趣的概念。

获取原文
获取原文并翻译 | 示例
           

摘要

We commend Elgene Lim and colleagues for providing a comprehensive review on the natural history of hormone receptor-positive breast cancer, highlighting the molecular and clinical heterogeneity of this disease, gaps in our understanding of its underlying biology, and challenges in research and clinical practice. We echo the sentiment that progress in treatment of hormone receptor-positive breast cancer has been slow and the impact of newer endocrine therapy approaches, such as the introduction of aromatase inhibitors (AIs) in the adjuvant setting and extended adjuvant therapy, on relapse and survival has been modest. Additionally, despite progress in the molecular profiling of breast cancer and subclassi-fication of ER-positive disease into luminal A and lumi-nal B subtypes, existing molecular assays have not raised new therapeutic hypotheses.
机译:我们赞扬Elgene Lim及其同事对激素受体阳性乳腺癌的自然史进行了全面的综述,强调了该疾病的分子和临床异质性,我们对其基本生物学认识的不足以及研究和临床实践中的挑战。我们赞同这样一种观点,即激素受体阳性乳腺癌的治疗进展缓慢,并且新的内分泌治疗方法(例如在辅助治疗中引入芳香酶抑制剂(AIs)和延长辅助治疗)对复发和生存的影响一直很谦虚。另外,尽管在乳腺癌的分子谱分析和将ER阳性疾病亚类化为腔A和发光B亚型方面取得了进展,但是现有的分子测定并未提出新的治疗假说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号